Ticker > Company >

Jagsonpal Pharma share price

Jagsonpal Pharmaceuticals Ltd.

NSE: JAGSNPHARM BSE: 507789 SECTOR: Pharmaceuticals & Drugs  60k   154   17

231.85
-2.75 (-1.17%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 236.2

Today's Low

₹ 229

52 Week High

₹ 328.02

52 Week Low

₹ 126

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1542.42 Cr.

Enterprise Value

1394.48 Cr.

No. of Shares

6.65 Cr.

P/E

27.86

P/B

6.43

Face Value

₹ 2

Div. Yield

1.08 %

Book Value (TTM)

₹  36.07

CASH

147.93 Cr.

DEBT

0 Cr.

Promoter Holding

67.78 %

EPS (TTM)

₹  8.32

Sales Growth

-11.83%

ROE

14.02 %

ROCE

17.72%

Profit Growth

-15.94 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-11.83%
3 Year3.55%
5 Year4.58%

Profit Growth

1 Year-15.94%
3 Year9.61%
5 Year25.5%

ROE%

1 Year14.02%
3 Year16.06%
5 Year14.35%

ROCE %

1 Year17.72%
3 Year21.04%
5 Year18.4%

Debt/Equity

0

Price to Cash Flow

43.86

Interest Cover Ratio

37.6941

CFO/PAT (5 Yr. Avg.)

1.38588074834271

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 67.78 0.00
Dec 2024 67.81 0.00
Sep 2024 67.97 0.00
Jun 2024 68.04 0.00
Mar 2024 68.09 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 21.0357666666667% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 37.6941.
  • The company has an efficient Cash Conversion Cycle of -0.266400000000004 days.
  • Company has a healthy liquidity position with current ratio of 6.8953.
  • The company has a good cash flow management; CFO/PAT stands at 1.38588074834271.
  • The company has a high promoter holding of 67.78%.

 Limitations

  • The company has shown a poor profit growth of 9.60844160043988% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.55347191047168% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 43.49 61.44 74.69 74.03 58.56
Total Expenditure 40.82 51.2 58.41 58.19 49.85
Operating Profit 2.67 10.24 16.29 15.83 8.71
Other Income 2.49 1.44 1.65 2.32 2.77
Interest 0.22 0.22 0.23 0.26 0.26
Depreciation 0.4 1.07 2.34 2.41 2.31
Exceptional Items 0 -3.29 0 23.18 -0.21
Profit Before Tax 4.54 7.11 15.37 38.67 8.71
Tax 0.99 1.78 3.91 6.68 2.13
Profit After Tax 3.55 5.33 11.46 31.99 6.58
Adjusted EPS (Rs) 0.54 0.81 1.73 1.93 0.99

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 158.57 187.95 217.58 236.71 208.7
Total Expenditure 150.04 168.87 192.56 202.56 185.64
Operating Profit 8.53 19.08 25.03 34.15 23.07
Other Income 2.53 4.39 3.43 5.73 9.28
Interest 0.51 0.51 0.29 0.41 0.81
Depreciation 1.13 1.09 1.53 1.21 1.66
Exceptional Items 0 0 0 -3.46 0
Profit Before Tax 9.41 21.87 26.64 34.81 29.87
Tax 1.54 4.81 7.79 8.09 7.41
Net Profit 7.87 17.06 18.86 26.72 22.46
Adjusted EPS (Rs.) 1.2 2.6 2.88 4.08 3.4

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 13.1 13.1 13.1 13.1 13.22
Total Reserves 97.93 108.83 119.66 145.79 174.18
Borrowings 0 0 0 0 0
Other N/C liabilities 3.09 1.88 4.49 8.49 10.55
Current liabilities 34.57 40.4 34.14 35.18 27.64
Total Liabilities 148.69 164.2 171.4 202.56 225.59
Assets
Net Block 24.44 25.72 22.6 24.28 9.3
Capital WIP 1.9 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 11.39 12.06 28.86 1.12 0
Loans & Advances 14.53 5.66 1.07 0.69 1.72
Other N/C Assets 0.13 0.29 2.62 4.29 23.99
Current Assets 96.31 120.48 116.25 172.17 190.59
Total Assets 148.69 164.2 171.4 202.56 225.59
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 9.41 21.87 26.64 34.81 29.87
Adjustment -0.57 -2.09 -1.4 9.63 8.27
Changes in Assets & Liabilities 4.84 11.59 -11.46 9.5 5.54
Tax Paid -1.8 -3.15 -6.87 -7.28 -8.51
Operating Cash Flow 11.89 28.22 6.91 46.66 35.17
Investing Cash Flow -11.07 -2.26 -25.78 -57.67 -24.55
Financing Cash Flow -1.82 -6.83 -17.55 -0.46 -8.91
Net Cash Flow -1.01 19.13 -36.42 -11.47 1.71

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 68.09 68.04 67.97 67.81 67.78
aresko progressive privat... 20.18 20.16 20.14 20.09 20.08
infinity holdings 25.01 25.00 16.66 16.62 16.62
infinity holdings sidecar... 17.99 17.97 17.95 17.91 17.90
infinity portfolio holdin... - - 8.64 8.62 8.61
rajpal singh kochhar 4.58 4.58 4.58 4.57 4.56
infinity consumer holding... 0.33 0.33 - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 31.91 31.96 32.03 32.19 32.22
authum investment and inf... 1.46 1.46 1.46 1.46 1.46
investor education and pr... - 1.55 1.54 1.54 1.54
lincoln p coelho 1.17 - 1.17 - 1.17
manish gupta 1.92 2.30 2.39 - 2.49
mukul mahavir agrawal 1.75 - 1.75 - 1.74
sanjiv kumar dudeja 1.40 - 1.40 - 1.40

Annual Reports

Title Action
Annual Report 2023
Annual Report 2022
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit ICRA
Credit ICRA
TYPE AGENCY ACTION
No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY25
Concall Q3FY25
TYPE QUARTER ACTION
Presentation Q3FY25
Presentation Q3FY22
Presentation Q2FY25
Presentation Q2FY25
Presentation Q2FY24

Company News

 No Latest News available for this company.
Report us

Jagsonpal Pharma Stock Price Analysis and Quick Research Report. Is Jagsonpal Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jagsonpal Pharma and its performance over the period of time. Jagsonpal Pharma stock price today is Rs 232.95.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Jagsonpal Pharma cash from the operating activity was Rs 35.166 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jagsonpal Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jagsonpal Pharma , the EPS growth was -16.6977 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jagsonpal Pharma has OPM of 11.05260131671 % which is a bad sign for profitability.
     
  • ROE: Jagsonpal Pharma have a average ROE of 14.0194 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Jagsonpal Pharma is Rs 232.95. One can use valuation calculators of ticker to know if Jagsonpal Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Jagsonpal Pharma
X